First in vivo gene-editing drugs enter the clinic
Nature Reviews Drug Discovery 17, 7 (2018).
doi:10.1038/nrd.2017.268
Author: Asher Mullard
Sangamo Therapeutics has started dosing patients with gene-editing drugs that are administered directly into the blood.Sangamo's zinc finger nucleases (ZFNs) are enzymes that selectively bind, cleave and enable the directed repair of DNA to knock genes both in and out of patient genomes. In
Source: Nature Reviews Drug Discovery - Category: Drugs & Pharmacology Authors: Asher Mullard Tags: News and Analysis Source Type: research